Search Results - "Lopez‐Rios, Fernando"

Implementing TMB measurement in clinical practice: considerations on assay requirements by Büttner, Reinhard, Longshore, John W, López-Ríos, Fernando, Merkelbach-Bruse, Sabine, Normanno, Nicola, Rouleau, Etienne, Penault-Llorca, Frédérique

“…Clinical evidence demonstrates that treatment with immune checkpoint inhibitor immunotherapy agents can have considerable benefit across multiple tumours…”
Get full text

Optimizing tissue stewardship in non‐small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists by Kerr, Keith M, Bubendorf, Lukas, Lopez‐Rios, Fernando, Khalil, Farah, Roy‐Chowdhuri, Sinchita, Joubert, Philippe, Hartmann, Arndt, Guerini‐Rocco, Elena, Yatabe, Yasushi, Hofman, Paul, Cooper, Wendy A, Dacic, Sanja

“…Many patients with non‐small cell lung cancer do not receive guideline‐recommended, biomarker‐directed therapy, despite the potential for improved clinical…”
Get full text

Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer by Pros, Eva, Lantuejoul, Sylvie, Sanchez‐Verde, Lydia, Castillo, Sandra D, Bonastre, Ester, Suarez‐Gauthier, Ana, Conde, Esther, Cigudosa, Juan C, Lopez‐Rios, Fernando, Torres‐Lanzas, Juan, Castellví, Josep, Cajal, Santiago Ramon y, Brambilla, Elisabeth, Sanchez‐Cespedes, Montse

“…Growth factor receptors (GFRs) are amenable to therapeutic intervention in cancer and it is important to select patients appropriately. One of the mechanisms…”
Get full text

Testing for ROS1 in non-small cell lung cancer: a review with recommendations by Bubendorf, Lukas, Büttner, Reinhard, Al-Dayel, Fouad, Dietel, Manfred, Elmberger, Göran, Kerr, Keith, López-Ríos, Fernando, Marchetti, Antonio, Öz, Büge, Pauwels, Patrick, Penault-Llorca, Frédérique, Rossi, Giulio, Ryška, Aleš, Thunnissen, Erik

“…Rearrangements of the ROS1 gene occur in 1–2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is…”
Get full text

Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing by Lopez-Beltran, Antonio, López-Rios, Fernando, Montironi, Rodolfo, Wildsmith, Sophie, Eckstein, Markus

“…Immuno-oncology (IO) agents (anti-programmed cell death 1 (PD-1) and anti-programmed cell death-ligand 1 (PD-L1)) are approved as first- and second-line…”
Get full text

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee by Mino-Kenudson, Mari, Schalper, Kurt, Cooper, Wendy, Dacic, Sanja, Hirsch, Fred R, Jain, Deepali, Lopez-Rios, Fernando, Tsao, Ming Sound, Yatabe, Yasushi, Beasley, Mary Beth, Yu, Hui, Sholl, Lynette M, Brambilla, Elizabeth, Chou, Teh-Ying, Connolly, Casey, Wistuba, Ignacio, Kerr, Keith M, Lantuejoul, Sylvie

“…Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of treatment for most lung cancers with advanced or metastatic disease. In…”
Get more information

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract by Sternberg, Cora N., Loriot, Yohann, James, Nicholas, Choy, Ernest, Castellano, Daniel, Lopez-Rios, Fernando, Banna, Giuseppe L., De Giorgi, Ugo, Masini, Cristina, Bamias, Aristotelis, Garcia del Muro, Xavier, Duran, Ignacio, Powles, Thomas, Gamulin, Marija, Zengerling, Friedemann, Geczi, Lajos, Gedye, Craig, de Ducla, Sabine, Fear, Simon, Merseburger, Axel S.

“…Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in…”
Get full text

Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung by Tang, Moying, Torres‐Lanzas, Juan, Lopez‐Rios, Fernando, Esteller, Manel, Sanchez‐Cespedes, Montserrat

“…Promoter hypermethylation is responsible for gene inactivation during carcinogenesis. It has been proposed that there is some degree of specificity in the set…”
Get full text

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group by Dietel, Manfred, Bubendorf, Lukas, Dingemans, Anne-Marie C, Dooms, Christophe, Elmberger, Göran, García, Rosa Calero, Kerr, Keith M, Lim, Eric, López-Ríos, Fernando, Thunnissen, Erik, Van Schil, Paul E, von Laffert, Maximilian

“…There is currently no Europe-wide consensus on the appropriate preanalytical measures and workflow to optimise procedures for tissue-based molecular testing of…”
Get more information

Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab by GOMEZ-MARTIN, Carlos, PLAZA, Jose Carlos, GALAN, M. Carmen, DEL VALLE, Elena, VILARDELL, Felipe, IGLESIAS, Mar, FERNANDEZ, Soledad, LANDOLFI, Stefania, CUATRECASAS, Miriam, MAYORGA, Marta, PAULES, M. Jose, SANZ-MONCASI, Pilar, PAZO-CID, Roberto, MONTAGUT, Clara, GARRALDA, Elena, ROJO, Federico, HIDALGO, Manuel, LOPEZ-RIOS, Fernando, SALUD, Antonieta, PONS, Francesc, FONSECA, Paula, LEON, Ana, ALSINA, Maria, VISA, Laura, RIVERA, Fernando

“…Previous studies have highlighted the importance of an appropriate human epidermal growth factor receptor 2 (HER2) evaluation for the proper identification of…”
Get full text

Genomic Profiling of HER2‐Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2‐Positive Advanced Gastric Cancer Treated with Trastuzumab by Díaz‐Serrano, Asunción, Angulo, Barbara, Dominguez, Carolina, Pazo‐Cid, Roberto, Salud, Antonieta, Jiménez‐Fonseca, Paula, Leon, Ana, Galan, Maria Carmen, Alsina, Maria, Rivera, Fernando, Plaza, J. Carlos, Paz‐Ares, Luis, Lopez‐Rios, Fernando, Gómez‐Martín, Carlos

“…Background HER2‐positive gastric cancer (GC) affects 7%–34% of patients with GC. Trastuzumab‐based first‐line treatment has become the standard of care for…”
Get full text

Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges by Mielgo-Rubio, Xabier, Martín, Margarita, Remon, Jordi, Higuera, Oliver, Calvo, Virginia, Jarabo, José Ramón, Conde, Esther, Luna, Javier, Provencio, Mariano, De Castro, Javier, López-Ríos, Fernando, Hernando-Trancho, Florentino, Couñago, Felipe

“…Lung cancer continues to be the leading cause of cancer mortality and a serious health problem despite the numerous advances made in the last decade and the…”
Get full text

Novel Transcriptional Targets of the SRY-HMG Box Transcription Factor SOX4 Link Its Expression to the Development of Small Cell Lung Cancer by CASTILLO, Sandra D, MATHEU, Ander, MARIANI, Niccolo, CARRETERO, Julian, LOPEZ-RIOS, Fernando, LOVELL-BADGE, Robin, SANCHEZ-CESPEDES, Montse

“…The HMG box transcription factor SOX4 involved in neuronal development is amplified and overexpressed in a subset of lung cancers, suggesting that it may be a…”
Get full text

Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment by GARRALDA, Elena, PAZ, Keren, BRUCKHEIMER, Elizabeth, ANGIUOLI, Samuel V, CALLES, Antonio, DIAZ, Luis A, VELCULESCU, Victor E, VALENCIA, Alfonso, SIDRANSKY, David, HIDALGO, Manuel, LOPEZ-CASAS, Pedro P, JONES, Siân, KATZ, Amanda, KANN, Lisa M, LOPEZ-RIOS, Fernando, SARNO, Francesca, AL-SHAHROUR, Fátima, VASQUEZ, David

“…Current technology permits an unbiased massive analysis of somatic genetic alterations from tumor DNA as well as the generation of individualized mouse…”
Get full text

A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond by Gomez-Martín, Carlos, Lopez-Rios, Fernando, Aparicio, Jorge, Barriuso, Jorge, García-Carbonero, Rocio, Pazo, Roberto, Rivera, Fernando, Salgado, Mercedes, Salud, Antonieta, Vázquez-Sequeiros, Enrique, Lordick, Florian

“…Highlights • HER2 positive gastric cancer is associated with a specific phenotype. • Reliable HER2 testing is mandatory for the correct use of anti-HER2…”
Get full text

MicroRNA-dependent regulation of transcription in non-small cell lung cancer by Molina-Pinelo, Sonia, Gutiérrez, Gabriel, Pastor, Maria Dolores, Hergueta, Marta, Moreno-Bueno, Gema, García-Carbonero, Rocío, Nogal, Ana, Suárez, Rocío, Salinas, Ana, Pozo-Rodríguez, Francisco, Lopez-Rios, Fernando, Agulló-Ortuño, Maria Teresa, Ferrer, Irene, Perpiñá, Asunción, Palacios, José, Carnero, Amancio, Paz-Ares, Luis

“…Squamous cell lung cancer (SCC) and adenocarcinoma are the most common histological subtypes of non-small cell lung cancer (NSCLC), and have been traditionally…”
Get full text

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab by Toledo, Rodrigo A, Cubillo, Antonio, Vega, Estela, Garralda, Elena, Alvarez, Rafael, de la Varga, Lisardo U, Pascual, Jesús R, Sánchez, Gema, Sarno, Francesca, Prieto, Susana H, Perea, Sofía, Lopéz-Casas, Pedro P, López-Ríos, Fernando, Hidalgo, Manuel

“…Cancer genomics and translational medicine rely on the molecular profiling of patient's tumor obtained during surgery or biopsy. Alternatively, blood is a less…”
Get full text

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model by Rajeshkumar, N V, Rasheed, Zeshaan A, García-García, Elena, López-Ríos, Fernando, Fujiwara, Kosaku, Matsui, William H, Hidalgo, Manuel

“…Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy with one of the worst outcomes among all cancers. PDA often recurs after initial treatment…”
Get full text

Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers by Arriola, Edurne, Bernabé, Reyes, Campelo, Rosario García, Biscuola, Michele, Enguita, Ana Belén, López-Ríos, Fernando, Martínez, Rafael, Mezquita, Laura, Palanca, Sarai, Pareja, María Jesús, Zugazagoitia, Jon, Arrabal, Natalia, García, J Francisco, Carcedo, David, de Álava, Enrique

“…The aim of this study was to assess the cost-effectiveness of using next-generation sequencing (NGS) versus single-gene testing (SgT) for the detection of…”
Get more information

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences by Garrido, Pilar, Olmedo, María Eugenia, Gómez, Ana, Paz Ares, Luis, López-Ríos, Fernando, Rosa-Rosa, Juan Manuel, Palacios, José

“…KRAS mutations represent one of the most prevalent oncogenic driver mutations in non-small cell lung cancer (NSCLC). For many years we have unsuccessfully…”
Get full text